Search Results

IN THIS EDITION:
Greater Role for Umbilical Cord Blood in Adult Transplants
Mary Eapen, Medical College of Wisconsin, Milwaukee
COMMENT: Armand Keating, University of Toronto

Ex Vivo Expansion Of Cord Blood Derived Progenitor Cells: Patient Transplant Data
Colleen Delaney, Fred Hutchinson Cancer Research Center, Seattle
COMMENT: Armand Keating

Erythropoiesis Stimulating Agents in Cancer Patients: Meta-Analysis Mortality Findings
Julia Bohlius, University of Bern
ON BEHALF OF: Erythropoiesis Stimulating Agents Individual Patient Data (EPO IPD) Meta-Analysis Collaborative Group
COMMENTS: Linda Burns, University of Minnesota, Minneapolis
George Canellos, Dana-Farber Cancer Institute, Boston

Imatinib: Durable Responses And Survival in Chronic Myeloid Leukemia: 7-Year IRIS Study Results; Can Imatinib Be Stopped?
Stephen O’Brien, Newcastle University, England

Armand Keating

Colleen Delaney

Julia Bohlius

George Canellos

Stephen O’Brien

The exciting recent ASH conference reflected the vibrant mood of an America boldly tackling economic and political turmoil with post-presidential-election optimism. Peter Goodwin and George Canellos reflect on some of the big stories and talk with key investigators in San Francisco. Francesco Zaja recounts how rituximab has proved effective for treating immune thrombocytopenic purpura (ITP); Hannes Wandt presents compelling data suggesting that platelet transfusions can be withheld in many patients receiving stem cell transplants for their hematologic malignancies; and both Michael Hallek and Tadeusz Robak announce Phase III study findings of improved benefits for patients whose chronic lymphocytic leukemia has been treated by adding rituximab to standard chemotherapy. The ASH President, Kenneth Kaushansky, plus Linda Burns and George Canellos contribute their comments to put the new findings into clinical perspective for the busy oncologist.

Kenneth Kaushansky

George Canellos

Hannes Wandt

Linda Burns

Scientific Editors:
George Canellos, Dana-Farber Cancer Institute, Boston
Gordon McVie, European Institute of Oncology, Milan
Pat Price, Christie Hospital, Manchester
Gianni Bonadonna, Istituto Nazionale Tumori, Milan

Sarah Maxwell and Peter Goodwin report on evidence that combining monoclonal antibodies with chemotherapy can extend life among patients with advanced non-small-cell lung cancer. Robert Pirker from the Medical University of Vienna tells Sarah Maxwell about his group’s findings in the FLEX study using the epidermal growth factor receptor (EGF-R) inhibitor cetuximab; Christian Manegold from Heidelberg University, Manheim gives Peter Goodwin data on the vascular endothelial growth factor (VEGF-R) bevacizumab; while Giorgio Scagliotti from Torino University, Nick Thatcher from the Christie Hospital, Manchester and Howard Sandler from the University of Michigan, Ann Arbor discuss the clinical implications of these approaches to using molecular targeting to improve outcomes in advanced non-small-cell lung cancer. Michel Coleman from the London School of Hygiene and Tropical Medicine tells Peter Goodwin about the findings of the CONCORD study looking at international differences between survival rates for breast, prostate and colorectal cancers.

Christian Manegold

Giorgio Scagliotti

Nick Thatcher

Michel Coleman